There appears to be no evidence that blood pressure–lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic, which was presented at the European Society of Cardiology Congress 2020.1
“Our results should reassure the public about the safety of antihypertensive drugs with respect to cancer, which is of paramount importance given their proven benefit for protecting against heart attacks and strokes,” said study author Emma Copland, MSc, an epidemiologist at the University of Oxford, United Kingdom.
Emma Copland, MSc
A potential link between blood pressure drugs and cancer has been debated for more than 40 years. The evidence for an increased or decreased risk of cancer with the use of antihypertensive medication has been inconsistent and conflicting.
This was the largest study on cancer outcomes in participants of randomized trials investigating antihypertensive medication—around 260,000 people in 31 trials. Investigators of all trials were asked for information on which participants developed cancer.
Study Details
Five antihypertensive drug classes were investigated separately: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, calcium channel blockers (CCBs), and diuretics. The investigators estimated the effect of each drug class on the risk of developing any type of cancer; of dying of cancer; and of developing breast, colorectal, lung, prostate, and skin cancers. They also examined whether there were any differences based on age, gender, body size, smoking status, and previous antihypertensive medication use before participants took part in the trial.
During an average of 4 years, there were about 15,000 new diagnoses of cancer. The researchers found no evidence that the use of any antihypertensive drug class increased the risk of cancer. This finding was consistent regardless of age, gender, body size, smoking status, and previous antihypertensive medication use.Each drug class was compared against all other control groups, including placebo, standard treatment, and other drug classes.
There appeared to be no important effect of any individual drug class on overall cancer risk. The hazard ratio for any cancer was 0.99 (95% confidence interval [CI]) = 0.94–1.04) with ACE inhibitors, 0.97 (95% CI = 0.93–1.02) with ARBs, 0.98 (95% CI = 0.89–1.08) with beta blockers, 1.06 (95% CI = 1.01–1.11) with CCBs, and 1.01 (95% CI = 0.95–1.07) with diuretics. In statistical terms, these effect sizes were not significantly different from each other, so there was no evidence of an increased risk of cancer with any of the drug classes.
Similarly, there was no evidence that any type of antihypertensive durg had an effect on the probability of developing breast, colorectal, lung, prostate, or skin cancer. When participants were followed throughout the course of each trial, there was no indication the risk of cancer increased with longer duration of use of these treatments.
DISCLOSURE: Ms. Copland reported no conflicts of interest.
Reference
1. Antihypertensive treatment and risk of cancer: An individual participant meta-analysis of 260,000 participants from 31 randomised clinical trials. Available at https://www.escardio.org. Accessed September 1, 2020.
